SGLT2 inhibitors, which are a novel class of antihyperglycemic drug, have been surprisingly found to significantly reduce hospitalizations for HF and cardiovascular mortality in patients with HF-rEF, which is potentially due to their numerous pleiotropic effects. The gene discussed is SLC5A2; the disease is hydrops fetalis.